Pharmacodynamic Effects of Prasugrel Compared With Ticagrelor in Patients With Coronary Artery Disease
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
Recently, two P2Y12 receptor inhibitors have been approved for clinical use: prasugrel and
ticagrelor. Both prasugrel and ticagrelor have shown to be associated with more potent
antiplatelet effects compared with clopidogrel and are associated with an improved net
clinical benefit. However, to date there are limited head-to-head comparisons of these two
new agents.